lapatinib has been researched along with 2019 Novel Coronavirus Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| AlAjmi, MF; Hussain, A; Rehman, MT | 1 |
| Asantewaa, G; Ciesla, JH; Dewhurst, S; Harris, IS; Leach, J; Lutz, MM; Monaghan, M; Munger, J; Raymonda, MH; Schafer, XL; Smorodintsev-Schiller, LA; Takimoto, T | 1 |
| Alem, F; Bhalla, N; Boghdeh, NA; Brown, JA; Chiem, K; Chiu, W; Cohen, CA; Das, S; De Jonghe, S; Durán, V; Dye, JM; Einav, S; Ghita, L; Ghosh, P; Huang, PT; Huie, KE; Jin, J; Jochmans, D; Karim, M; Khalil, AM; Kumar, S; Leyssen, P; Lo, CW; Martinez-Sobrido, L; Narayanan, A; Neyts, J; Pinsky, BA; Saul, S; Sibai, M; Solow-Cordero, DE; Tindle, C; Tran, DH; Wikswo, JP; Ye, C | 1 |
| Ding, K; Loftin, C; Yuan, Y; Zhan, CG; Zheng, F; Zhou, S; Zhou, Z | 1 |
4 other study(ies) available for lapatinib and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Celecoxib, Glipizide, Lapatinib, and Sitagliptin as potential suspects of aggravating SARS-CoV-2 (COVID-19) infection: a computational approach.
Topics: Angiotensin-Converting Enzyme 2; Celecoxib; COVID-19; Glipizide; Humans; Lapatinib; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; SARS-CoV-2; Sitagliptin Phosphate | 2022 |
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Benzoquinones; Cell Line; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Discovery; Drug Synergism; High-Throughput Screening Assays; Humans; Lactams, Macrocyclic; Lapatinib; Naphthalenes; Phenylurea Compounds; Pyrazoles; RNA, Viral; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |
Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects.
Topics: Animals; Antiviral Agents; COVID-19; Cytokines; Hepatitis C, Chronic; Humans; Inflammation; Lapatinib; Mice; SARS-CoV-2 | 2023 |
DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.
Topics: Anti-Inflammatory Agents; Betacoronavirus; Computational Chemistry; Coronavirus Infections; COVID-19; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Repositioning; Humans; Inflammation; Lapatinib; Molecular Dynamics Simulation; Pandemics; Pneumonia, Viral; Prostaglandin-E Synthases; SARS-CoV-2 | 2020 |